A prospective controlled study for tranexamic acid versus gelatin gel in maintaining peri-operative hemostasis in musculoskeletal tumor surgery

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029374

Enrollment

Unknown

Registered

2020-01-15

Start date

2020-01-07

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

musculoskeletal tumor

Interventions

Group A:tranexamic acid

Group B:Gelatin gel

Eligibility

Sex/Gender

All

Age

7 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with primary benign or malignant tumors of bone or soft tissue who received surgical treatment. Surgical treatment includes tumor resection, curettage, resection and curettage, autogenous bone transplantation, plate and screw internal fixation, intramedullary nail fixation, joint and prosthesis replacement, implantation of foreign implants and amputation

Exclusion criteria

Exclusion criteria: 1. Tumor arising from Haematopoietic origin; 2. estimated blood loss less than 200 ml; 3. allergic to tranexamic acid or gelatin gel.

Design outcomes

Primary

Measure	Time frame
haemorrhagia amount;	—

Countries

China

Contacts

Public ContactDuan Hong

West China Hospital, Sichuan University

duanhong1970@126.com+18 18980601402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026